MacroGenics, Inc.
Status: Publicly traded
Direct answer
MacroGenics, Inc. is publicly traded on NASDAQ under the ticker MGNX.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for...
Can you invest in MacroGenics, Inc.?
Yes. MacroGenics, Inc. is publicly traded on NASDAQ under the ticker MGNX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for MacroGenics, Inc.
Detailed equity research is provided by MarketSnap.